Document and Entity Information	9 Months Ended
Document and Entity Information	Feb. 28, 2014	Apr. 01, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 28, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,416,167

Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Income Statement [Abstract]
Net sales	$ 88,195	$ 81,571	$ 260,390	$ 251,994
Cost of sales	42,560	40,370	127,343	127,247
Gross profit	45,635	41,201	133,047	124,747
Operating expenses
Research and development	7,045	5,793	20,757	19,881
Sales and marketing	20,700	18,520	61,736	55,734
General and administrative	6,231	6,046	19,082	19,854
Amortization of intangibles	4,248	4,314	12,871	11,961
Change in fair value of contingent consideration	(4,154)	630	(2,481)	827
Acquisition, restructuring and other items, net	3,016	5,157	7,697	9,943
Medical device excise tax	980	683	2,955	683
Total operating expenses	38,066	41,143	122,617	118,883
Operating income	7,569	58	10,430	5,864
Other (expenses) income
Interest expense	(917)	(1,271)	(3,122)	(3,986)
Interest income				103
Other expense	(1,068)	(608)	(2,457)	(1,824)
Total other expenses, net	(1,985)	(1,879)	(5,579)	(5,707)
Income (loss) before income tax expense (benefit)	5,584	(1,821)	4,851	157
Income tax expense (benefit)	476	(829)	268	(99)
Net income (loss)	$ 5,108	$ (992)	$ 4,583	$ 256
Income (loss) per share
Basic	$ 0.15	$ (0.03)	$ 0.13	$ 0.01
Diluted	$ 0.14	$ (0.03)	$ 0.13	$ 0.01
Basic weighted average shares outstanding	35,184	34,834	35,088	34,787
Diluted weighted average shares outstanding	35,704	34,834	35,372	35,315

Consolidated Statements of Comprehensive Income (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net Income (Loss)	$ 5,108	$ (992)	$ 4,583	$ 256
Other comprehensive income (loss), before tax:
Unrealized gain (loss) on interest rate swap	132	187	(71)	(871)
Unrealized gain (loss) on marketable securities	(18)		(18)	184
Foreign currency translation gain (loss)	106	(157)	246	(34)
Other comprehensive income (loss), before tax	220	30	157	(721)
Income tax (expense) benefit related to items of other comprehensive income	(42)	(69)	33	254
Other comprehensive income (loss), net of tax	178	(39)	190	(467)
Total comprehensive income (loss), net of tax	$ 5,286	$ (1,031)	$ 4,773	$ (211)

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Feb. 28, 2014	May 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$ 7,382	$ 21,802
Marketable securities	1,807	2,153
Accounts receivable, net of allowances of $1,553 and $1,272 respectively	57,726	47,791
Inventories	59,834	55,062
Deferred income taxes	3,656	6,591
Prepaid income taxes	2,727	563
Prepaid expenses and other	6,999	7,554
Total current assets	140,131	141,516
PROPERTY, PLANT AND EQUIPMENT-AT COST, net	66,478	62,650
OTHER ASSETS	5,592	5,559
INTANGIBLE ASSETS, net	207,970	214,848
GOODWILL	359,736	355,458
DEFERRED INCOME TAXES, long term	11,721	11,007
PREPAID ROYALTIES	546	546
TOTAL ASSETS	792,174	791,584
CURRENT LIABILITIES
Accounts payable	25,506	24,522
Accrued liabilities	18,966	16,426
Income Taxes Payable	879
Current portion of long-term debt	5,000	7,500
Current portion of contingent consideration	12,146	9,207
Other current liabilities	883	5,782
Total current liabilities	63,380	63,437
LONG-TERM DEBT, revolving credit facility	41,410
LONG-TERM DEBT, term loan, net of current portion	92,500	135,000
DEFERRED INCOME TAXES, long term	1,166
Contingent consideration, net of current portion	55,841	65,842
Other long term liabilities	188	475
Total liabilities	254,485	264,754
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $.01 per share, 45,000,000 shares authorized; issued and outstanding 35,416,043 and 35,060,351 shares at February 28, 2014 and May 31, 2013, respectively	353	351
Additional paid-in capital	506,638	500,554
Retained earnings	34,146	29,563
Treasury stock, 142,305 shares, at cost	(2,104)	(2,104)
Accumulated other comprehensive loss	(1,344)	(1,534)
Total stockholders' equity	537,689	526,830
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 792,174	$ 791,584

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Feb. 28, 2014	May 31, 2013
Statement Of Financial Position [Abstract]
Accounts receivable, allowances	$ 1,553	$ 1,272
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	35,416,043	35,060,351
Common stock, shares outstanding	35,416,043	35,060,351
Treasury stock, shares	142,305	142,305

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013
Cash flows from operating activities:
Net income	$ 4,583	$ 256
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,759	18,571
Stock based compensation	4,022	3,372
Change in fair value of contingent consideration	(2,481)	827
Deferred income taxes	2,219	3,419
Change in accounts receivable allowances	281	30
Tax effect on exercise of stock options and issuance of performance shares	(146)	(422)
Other	(50)	119
Loss on discontinuance of product offering		1,576
Gain on sale of assets		(801)
Amortization of acquired inventory basis step-up	150	3,845
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(9,693)	3,927
Inventories	(4,225)	(9,468)
Prepaid expenses and other	(944)	398
Accounts payable, accrued and other liabilities	2,699	(10,134)
Net cash provided by operating activities	15,174	15,515
Cash flows from investing activities:
Additions to property, plant and equipment	(9,003)	(7,708)
Acquisition of business, net of cash acquired	(4,169)	(24,624)
Collection of escrow receivable		2,500
Acquisition of intangible and other assets	(180)	(650)
Proceeds from disposal of intangible and other assets		801
Purchases of marketable securities	(25)	(5,134)
Proceeds from sale or maturity of marketable securities	353	16,989
Net cash used in investing activities	(13,024)	(17,826)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	100,000
Proceeds from borrowings on revolving credit facility	41,410
Repayment of long-term debt	(145,000)	(5,625)
Deferred financing costs on long-term debt	(677)
Payment of contingent consideration previously established in purchase accounting	(14,597)
Proceeds from exercise of stock options and employee stock purchase plan	2,208	1,096
Net cash used in financing activities	(16,656)	(4,529)
Effect of exchange rate changes on cash and cash equivalents	86	(43)
Decrease in cash and cash equivalents	(14,420)	(6,883)
Cash and cash equivalents at beginning of period	21,802	23,508
Cash and cash equivalents at end of period	7,382	16,625
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of intangibles and business	4,970	78,286
Contractual obligations for acquisition of fixed assets	$ 1,200	$ 1,878

Consolidated Statement of Stockholders' Equity (USD $) In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2013	$ 526,830	$ 351	$ 500,554	$ 29,563	$ (1,534)	$ (2,104)
Beginning Balance,Treasury Shares at May. 31, 2013	(142,305)
Beginning Balance, Shares at May. 31, 2013		35,060,351
Net income	4,583			4,583
Exercise of stock options	850		850
Exercise of stock options, Shares		82,767
Tax impact of stock option activity	(146)		(146)
Purchase of common stock under ESPP	1,359	1	1,358
Purchase of common stock under ESPP, Shares		146,275
Issuance of performance shares	1	1
Issuance of performance shares, Shares		126,650
Stock based compensation	4,022		4,022
Other comprehensive income, net of tax	190				190
Ending Balance at Feb. 28, 2014	$ 537,689	$ 353	$ 506,638	$ 34,146	$ (1,344)	$ (2,104)
Ending Balance,Treasury Shares at Feb. 28, 2014	(142,305)
Ending Balance, Shares at Feb. 28, 2014		35,416,043

Consolidated Financial Statements	9 Months Ended
Consolidated Financial Statements	Feb. 28, 2014
Accounting Policies [Abstract]
Consolidated Financial Statements	NOTE A – CONSOLIDATED FINANCIAL STATEMENTS The consolidated balance sheet as of February 28, 2014, the consolidated statement of stockholders’ equity and consolidated statement of cash flows for the nine months ended February 28, 2014, the consolidated statements of income and the consolidated statements of comprehensive income for the three and nine months ended February 28, 2014 and 2013 have been prepared by us without audit. The consolidated balance sheet as of May 31, 2013 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2014 (and for all periods presented) have been made. Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended May 31, 2013, filed by us on August 14, 2013. Our most significant accounting policies are disclosed in Note A to the consolidated financial statements included in the aforementioned Form 10-K for the fiscal year ended May 31, 2013. The results of operations in the fiscal periods ended February 28, 2014 and 2013 are not necessarily indicative of the operating results for the respective full fiscal years. The unaudited interim consolidated financial statements for the three and nine months ended February 28, 2014 and February 28, 2013 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, RITA Medical Systems, LLC, AngioDynamics UK Limited, AngioDynamics Netherlands B.V., NM Holding Company, Inc. (Navilyst), Vortex Medical, Inc. since October 15, 2012 and Clinical Devices B.V. since August 15, 2013, (collectively, the “Company”). All intercompany balances and transactions have been eliminated. *Recent Developments* Operational Excellence Program - On December 5, 2013, we announced a company-wide operational excellence program designed to save between $15 and $18 million during the course of the next three years and is expected to create greater efficiencies and drive business performance improvements. (See Note N for further information regarding this restructuring.) New Credit Agreement - On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Facility”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Facility, the “Facilities”). The proceeds of the Term Loan and a portion of the proceeds of the Revolving Facility were used to repay our Credit Agreement (the “Existing Credit Agreement”) dated as of May 22, 2012 with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five, respectively. Interest on both the Term Loan and Revolver will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolver will also carry a commitment fee of 0.20% to 0.35% per annum on the unused portion. Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors. On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Existing Credit Agreement. As of February 28, 2014, $92.5 million and $41.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of February 28, 2014. On September 19, 2013, we repaid all amounts owed under the Existing Credit Agreement, and as a result, the Existing Credit Agreement was terminated. Pursuant to the terms of the Existing Credit Agreement, we had the option to repay this facility at any time prior to the maturity date without penalty. (See Note F for further information on the Credit Agreement.) Acquisition of Clinical Devices, B.V. - On August 15, 2013 we acquired all the outstanding shares of stock of Clinical Devices, B.V., our exclusive distributor of our fluid management products in the Netherlands. The acquisition includes certain in-process research and development for a next-generation tip location technology. (See Note B for further information on the acquisition.) Regulatory Matters - On May 27, 2011, we received a Warning Letter from FDA in connection with its inspection of our Queensbury, NY manufacturing facility. In the Warning Letter, FDA cited deficiencies in the response letter we provided FDA pertaining to the inspection that occurred from January 4 to January 13, 2011. The deficiencies related to our internal procedures for medical device reporting, corrections and removals and complaint handling. We responded to the Warning Letter and completed corrective and preventive actions to address the observations noted. In December 2011, we initiated a comprehensive Quality Call to Action Program to review and augment our Quality Management Systems at our Queensbury facility. To accelerate implementation of the program, we engaged a team of external regulatory and quality experts and reallocated a significant number of engineering and product development resources to support this corporate initiative. From inception of the Quality Call to Action Program through fiscal 2013, we incurred $3.2 million in direct costs associated with the program. On February 10, 2012, we received from FDA a Form 483, List of Investigational Observations, in connection with its inspection of our Queensbury facility from November 14, 2011 to February 10, 2012. The Form 483 contained 12 observations related to, among other things, our CAPA (Corrective and Preventive Action) system, MDR (Medical Device Reporting), complaint investigation, corrections and removals, acceptance criteria and training. Some of the observations contained in the Form 483 were repeat observations from the May 27, 2011 Warning Letter. On February 13, 2012, we received from FDA a Form 483 in connection with its inspection of our Fremont facility from January 12, 2012 to February 13, 2012. The Form 483 contained six observations related to, among other things, our CAPA system, design controls, risk management and training. We provided responses to FDA within 15 business days of our receipt of the Form 483s. On September 24, 2012, we received from FDA a Form 483 in connection with its subsequent inspection of our Queensbury, NY facility from September 6 to September 14, and September 19 to September 24. This re-inspection followed our response to the original Form 483 issued by FDA on February 13, 2012. The Form 483 contained 5 observations related to 510(k) decisions, complaint investigations, acceptance criteria, corrective and preventive actions and training. All but one of the observations in the Form 483 related to events that occurred before the date that we had indicated to FDA in our previous responses that our corrective and remediation activities related to our Quality Call to Action would be completed. We provided responses to FDA within 15 business days of our receipt of the Form 483. On November 28, 2012, FDA completed an inspection of our Manchester, GA facility and no Form 483 observations were issued. On February 4, 2014, FDA completed a comprehensive follow-up inspection of our Queensbury facility. The inspection began on January 14, 2014 and resulted in FDA issuing a Form 483 containing one observation. The observation related to the inconsistency of certain complaint investigation elements in certain devices that have hardware and disposable components. The Form 483 observation was annotated to reflect that during the inspection we had corrected the issue, and this correction was verified by the inspector. In addition, we provided a response to FDA within 15 business days of our receipt of the Form 483. We believe that the results of this inspection validate that all of the Quality System and current Good Manufacturing Practice issues raised in the 483s described above have been fully addressed. On March 31, 2014, FDA completed an inspection of our Glens Falls, NY facility. The inspection began on March 17, 2014 and resulted in FDA issuing a form 483 containing 3 observations. The observations were related to 1) inconsistency of a manufacturing product test process used among similar products, 2) a particular verification test of a product, and 3) non-conforming product control procedure. We will be responding to FDA within 15 business days of the receipt of the Form 483. We will continue to work closely with FDA to resolve any outstanding issues. Unless the items raised in the previously disclosed Warning Letters and Form 483s are corrected to FDA’s satisfaction or we come to some other arrangement with FDA finally resolving such matters, we may be subject to additional regulatory or legal action, including the issuance of warning letters, injunction, seizure or recall of products, imposition of fines or penalties or operating restrictions on our facilities. Such actions could significantly disrupt our ongoing business and operations and have a material adverse impact on our financial position and operating results.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Acquisitions	9 Months Ended
Acquisitions	Feb. 28, 2014
Business Combinations [Abstract]
Acquisitions	NOTE B – ACQUISITIONS *Acquisition of Clinical Devices* On August 15, 2013 we acquired all the outstanding shares of capital stock of Clinical Devices, B.V., exclusive distributor of our fluid management products in the Netherlands. The stock purchase agreement provided for the payment of $3.7 million in cash at closing, which was subject to a working capital adjustment and $400,000 holdback, plus future earn out consideration payable in cash. Earn out consideration is based on our net sales of the fluid management products during the five quarters following the closing as well as milestone payments for achieving regulatory approvals of certain in process research and development for a next-generation tip location technology. The total purchase consideration of $8.7 million includes an upfront payment and the estimated fair value of contingent consideration of $5.0 million. (See Note J for additional information related to the contingent Earn out liability.) Goodwill recorded as a result of the acquisition was approximately $4.3 million and is not deductible for tax purposes. Intangible assets acquired, other than goodwill, totaled approximately $5.1 million, of which $3.6 million has been identified as in-process research and development (10-year estimated useful life), $1.4 million as customer relationships (15-year estimated useful life) and $100,000 as trademarks (5-year estimated useful life). We also recorded a deferred tax liability of $1.2 million. The acquisition has been accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective August 15, 2013. The pro-forma effects of the acquisition on our income statement and balance sheet were not material. *Acquisition of Microsulis Medical Ltd.* On March 22, 2012, we established a strategic relationship with Microsulis Medical Ltd. (“Microsulis”), a U.K.-based company specializing in minimally-invasive, microwave ablation technology for the coagulation of soft tissue. On February 1, 2013, we completed the acquisition of certain assets of Microsulis, which we have accounted for as a business combination, for cash payments at closing totaling $10.0 million, which was subject to a working capital adjustment, a $5.0 million payment on December 31, 2013 and potential additional cash consideration payable upon performance over the next nine years. We also assumed $1.6 million of liabilities. The total estimated purchase consideration of $33.6 million includes the initial investment of $5.0 million, closing payments totaling $10.5 million, a $5.0 million payment on December 31, 2013 and the estimated fair value of contingent consideration (Earn out) of $13.2 million. The $5.0 million payment was made on December 31, 2013. The estimated fair value of contingent consideration is based on projected net sales over the nine year period following the closing. The amount of the Earn out consideration that could be paid on net sales is not limited. (See Note J for additional information related to the contingent Earn out liability.) The estimated purchase consideration exceeded the fair value of the acquired net assets by $19.3 million and was recorded as goodwill. Goodwill associated with the acquisition of certain assets of Microsulis is deductible for tax purposes. Intangible assets are being amortized over their estimated useful lives which range from 10 to 15 years. During the nine month period ended February 28, 2014, we incurred acquisition related costs of $0.1 million which were expensed to “Acquisition, restructuring and other items, net” in the statement of income. *Acquisition of Vortex Medical, Inc.* On October 15, 2012, we acquired all the outstanding capital stock of Vortex Medical, Inc., a privately-held company focused on the development and commercialization of medical devices for venous drainage and the removal of thrombus, or blood clots, from occluded blood vessels. Vortex’s principal product is the AngioVac ^® system, which includes the AngioVac Cannula and Circuit. The AngioVac Cannula has a proprietary balloon-actuated, expandable, funnel-shaped distal tip that enhances flow, prevents clogging of the cannula and facilitates en bloc, or whole removal of undesirable intravascular material. Both the AngioVac Cannula and Circuit are FDA-cleared for use during extracorporeal bypass for up to 6 hours. CE Mark approval was received in December 2013. The total estimated purchase consideration of $75.3 million included the upfront payment of $15.1 million and the estimated fair value of contingent consideration of $60.3 million, $40 million of which is guaranteed. The estimated fair value of contingent consideration is based on projected AngioVac net sales in the ten year period following the closing. The amount of the Earn out consideration that could be paid on AngioVac net sales is not limited. (See Note J for additional information related to the contingent Earn out liability.) The purchase consideration exceeded the fair value of the acquired net assets by $29.5 million and was recorded as goodwill. Goodwill associated with the acquisition of Vortex’s stock is not deductible for tax purposes. Core technologies are being amortized over their estimated useful lives of approximately 15 years as revenues are earned from the sales of the related products.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Inventories

9 Months Ended

Feb. 28, 2014

Inventory Disclosure [Abstract]

Inventories

NOTE C – INVENTORIES

Inventories are stated at lower of cost (at standard cost which approximates the first-in, first-out method) or market. As of February 28, 2014 and May 31, 2013, inventories consisted of the following (in thousands of dollars):


	Feb 28, 2014		May 31, 2013
	(in thousands)
Raw materials	$	23,319	$	18,362
Work in process		13,353		11,006
Finished goods		23,162		25,694

Inventories	$	59,834	$	55,062

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Goodwill and Intangible Assets

9 Months Ended

Feb. 28, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

NOTE D – GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between three and fifteen years, on either a straight-line basis over the expected period of benefit or as revenues are earned from the sales of the related products. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Our determination of impairment is based on estimates of future cash flows. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs. Allocated costs were based on respective fair market values at the date of acquisition.

For goodwill, the impairment test requires a comparison of the estimated fair value of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge. Our determination of impairment is based on estimates of future cash flows.

To determine fair value, we considered two market-based approaches and an income approach. Under the market-based approaches, we utilized information regarding our own as well as publicly available industry information to determine earnings multiples and sales multiples. Under the income approach, we determined fair value based on estimated future cash flows of the reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We determined the discounted cash flow as the best indicator to determine fair value and therefore assigned a weight of 75% with the remaining 25% assigned to the market approach.

Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. These assumptions are highly sensitive and changes in these estimates could result in impairment. Solely for purposes of establishing inputs for the fair value calculations, we assumed that the current economic conditions would continue through fiscal year 2014, followed by a recovery thereafter. In addition, we applied gross margin assumptions, showing some improvement over historical trends, at various revenue levels and used an EBITDA exit multiple of 7.0 to calculate the terminal value of the reporting unit. In addition, we used a discount rate of 12% to calculate the fair value of our reporting unit.

We completed our annual goodwill impairment test as of December 31, 2013. At December 31, 2013, our reporting unit is the same as our reportable segment. Our assessment of goodwill impairment indicated that the fair value of our reporting unit exceeded its carrying value and therefore goodwill was not impaired. The fair value of our reporting unit exceeded its carrying value by 6%. The fair value of the reporting unit was reconciled to our current stock market capitalization as of December 31, 2013.

Since early November 2008, our stock market capitalization has at times been lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2014 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value.

We also completed our annual indefinite lived asset (NAMIC trademark) test as of December 31, 2013 using the income approach to determine fair value. Under this approach, the relief from royalty method was applied using a 5% long-term growth rate, a 3% royalty rate and a 12.5% discount rate. Our assessment of the NAMIC trademark indicated that the fair value exceeded the carrying value by 6% and therefore the asset was not impaired.

Even though we determined that there was no goodwill impairment as of December 31, 2013, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal factors or business climate, an adverse action or assessment by a regulator, unanticipated competition, a material negative change in relationships with significant customers, strategic decisions made in response to economic or competitive conditions, loss of key personnel or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2014.

It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material. Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region.

Adjustments to goodwill for the nine months ended February 28, 2014 are as follows (in thousands of dollars):


Balance, May 31, 2013	$	355,458
Acquisition of Clinical Devices B.V.		4,278

Balance, February 28, 2014	$	359,736

The above change in the carrying value of goodwill is the result of the acquisition of Clinical Devices, B.V. (See Note B.)

As of February 28, 2014 and May 31, 2013, intangible assets consisted of the following (in thousands of dollars, except weighted average useful life):


	February 28, 2014
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	150,363	$	(31,060	)	$	119,303		10.2
Customer relationships		86,688		(36,412	)		50,276		11.9
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		6,290		(4,762	)		1,528		9.0
Trademarks		6,345		(1,682	)		4,663		8.0
In-process R&D acquired		3,600		—			3,600		Indefinite
Distributor relationships		900		(900	)		—		3.0

	$	282,786	$	(74,816	)	$	207,970


	May 31, 2013
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	150,181	$	(24,835	)	$	125,346		10.6
Customer relationships		84,479		(30,595	)		53,884		14.8
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		6,302		(4,501	)		1,801		9.0
Trademarks		6,275		(1,058	)		5,217		9.9
Distributor relationships		900		(900	)		—		3.0

	$	276,737	$	(61,889	)	$	214,848

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

Accrued Liabilities

9 Months Ended

Feb. 28, 2014

Payables And Accruals [Abstract]

Accrued Liabilities

NOTE E – ACCRUED LIABILITIES

As of February 28, 2014 and May 31, 2013, accrued liabilities consisted of the following (in thousands of dollars):


	Feb 28, 2014		May 31, 2013
	(in thousands)
Payroll and related expenses	$	7,529	$	6,491
Royalties		2,279		2,034
Accrued severance		1,491		1,602
Deferred revenue		1,471		1,573
Sales and franchise taxes		1,091		1,047
Interest rate swap liability		594		523
Other		4,511		3,156

Total	$	18,966	$	16,426

Long Term Debt	9 Months Ended
Long Term Debt	Feb. 28, 2014
Debt Disclosure [Abstract]
Long Term Debt	NOTE F – LONG TERM DEBT New Credit Agreement - On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Loan”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the TermLoan, the “Facilities”). The proceeds of the Term Loan and a portion of the proceeds of the Revolving Facility were used to repay our Credit Agreement (the “Existing Credit Agreement”) dated as of May 22, 2012 with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers. The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolving Facility will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolving Facility will also carry a commitment fee of 0.20% to 0.35% per annum on the unused portion. Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors. In June 2012, we entered in an interest rate swap agreement, (the “Swap Agreement”), with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting under authoritative guidance, was a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement. On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Existing Credit Agreement. As of February 28, 2014, $92.5 million and $41.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of February 28, 2014. On September 19, 2013, we repaid all amounts owed under the Existing Credit Agreement, and as a result, the Existing Credit Agreement was terminated. Pursuant to the terms of the Existing Credit Agreement, we had the option to repay this facility at any time prior to the maturity date without penalty.

Income Taxes

9 Months Ended

Feb. 28, 2014

Income Tax Disclosure [Abstract]

Income Taxes

NOTE G – INCOME TAXES

The following table presents the components of income tax expense/(benefit) for the three and nine month periods ended February 28, 2014 and 2013 (in thousands of dollars):


	Three Months Ended						Nine Months Ended
	Feb 28, 2014			Feb 28, 2013			Feb 28, 2014			Feb 28, 2013

Income tax expense/(benefit) based on income/(loss) from continuing operations at estimated tax rates of 45.7% in 2014 and 70.3% in 2013	$	2,555		$	(1,280	)	$	2,217		$	110

Discrete tax expense/(benefit):

Non taxable gain on revaluation of contingent consideration liability at estimated tax rate of 45.7% in 2014		(2,285	)		—			(2,285	)		—

Adjustment for elimination of the ASC 718 APIC pool		57						123

Provision for change in projected tax rates		(50	)		601						—

Retroactive renewal of research and experimentation credit					(129	)					(129	)

Adjustments to prior period tax liabilities		156			(30	)		170			(3	)

Non deductible acquisition costs		—			9			—			102

Adjustment to fully reserved capital losses		43			—			43			(179	)


Total income tax expense/(benefit)	$	476		$	(829	)	$	268		$	(99	)

The third quarter estimated effective tax rate prior to discrete items was 45.7% in 2014, as compared to 70.3% for the same period in 2013. The change in the rate is primarily due to a magnified impact of non-deductible items (such as stock-based compensation and the non-deductible portion of meals and entertainment) caused by reduced taxable income in fiscal 2013. In addition, our ASC 718 APIC pool, which has been historically reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting, is fully depleted. This depletion resulted in a discrete tax expense in the third quarter of 2014.

We currently believe that we will generate taxable income in the future sufficient to realize the benefit of all of our deferred tax assets (consisting primarily of net operating loss carry forwards acquired from RITA, Navilyst and Vortex). However, some or all of these deferred tax assets could expire unused if we are unable to generate taxable income in the future sufficient to utilize them. The Company will need to generate $9.3 million of taxable income each year from 2015 to 2023 and then $6.5 million per year until 2031 in order to utilize all of our net operating loss carry forwards. If it becomes more likely than not that our deferred tax assets will expire unused,a valuation allowance will be recorded, which may significantly increase our income tax expense, and therefore adversely affect our results of operations in the period in which it is recorded.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Earnings Per Share

9 Months Ended

Feb. 28, 2014

Earnings Per Share [Abstract]

Earnings Per Share

NOTE H – EARNINGS PER SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options and restricted stock units, provided that the inclusion of such securities is not antidilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 28, 2014 and 2013 (in thousands):


	Three Months Ended				Nine Months Ended
	Feb 28, 2014		Feb 28, 2013		Feb 28, 2014		Feb 28, 2013
Basic		35,184		34,834		35,088		34,787
Effect of dilutive securities		520		—		284		528

Diluted		35,704		34,834		35,372		35,315

Excluded from the calculation of diluted earnings per common share are options and restricted stock awards issued to employees and non-employees to purchase 0.7 million and 2.3 million shares of common stock for the three and nine months ended February 28, 2014, as their inclusion would be antidilutive. For both the three and nine months ended February 28, 2013, options and restricted stock awards issued to employees and non-employees to purchase 2.9 million shares of common stock were also excluded as their inclusion would have been antidilutive.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Segment and Geographic Information

9 Months Ended

Feb. 28, 2014

Segment Reporting [Abstract]

Segment and Geographic Information

NOTE I – SEGMENT AND GEOGRAPHIC INFORMATION

We consider our business to be a single operating segment entity – the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

The table below summarizes net sales by product category (in thousands of dollars):


	Three Months Ended				Nine Months Ended
	Feb 28, 2014		Feb 28, 2013		Feb 28, 2014		Feb 28, 2013
Net sales
Peripheral Vascular	$	47,403	$	42,616	$	141,743	$	131,676
Vascular Access		27,259		26,391		78,113		79,733
Oncology/Surgery		11,968		10,449		35,692		33,688
Supply Agreement		1,565		2,115		4,842		6,897

Total	$	88,195	$	81,571	$	260,390	$	251,994

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):


	Three Months Ended				Nine Months Ended
	Feb 28, 2014		Feb 28, 2013		Feb 28, 2014		Feb 28, 2013
Net Sales
United States	$	69,859	$	63,784	$	206,491	$	196,682
International		16,771		15,672		49,057		48,415
Supply Agreement		1,565		2,115		4,842		6,897

Total	$	88,195	$	81,571	$	260,390	$	251,994

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Fair Value

9 Months Ended

Feb. 28, 2014

Fair Value Disclosures [Abstract]

Fair Value

NOTE J – FAIR VALUE

Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs related to the acquisitions of Vortex, Microsulis and Clinical Devices. The carrying amount of cash and cash equivalents, accounts receivable, marketable securities and accounts payable approximates fair value due to the immediate or short-term maturities. The interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. Marketable securities, with the exception of one auction rate securities, are carried at their fair value as determined by quoted market prices. The contingent earn out has been recorded at fair value using the income approach.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below.


Level 1		Quoted prices in active markets for identical assets or liabilities. Level 1 assets include bank time deposits, money market funds, mutual funds and U.S. Treasury securities that are traded in an active exchange market.

Level 2		Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets include US government securities and corporate bonds. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. Since many fixed income securities do not trade on a daily basis, the methodology of the pricing vendor uses available information as applicable such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. These investments are included in Level 2 and primarily comprise our portfolio of corporate and government fixed income securities. Additionally included in Level 2 are interest rate swap agreements which are valued using a mid-market valuation model.

Level 3		Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category currently includes the auction rate securities where independent pricing information was not able to be obtained and the contingent Earn out related to the acquisition of Vortex, Microsulis and Clinical Devices. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the amount and timing of future interest and principal payments, forward projections of the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk associated with auction-rate securities. The contingent earn outs were valued utilizing a discounted cash flow method as detailed below.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2014 and May 31, 2013 (in thousands of dollars):


	Fair Value Measurements using inputs considered as:						Fair Value at February 28, 2014
	Level 1		Level 2		Level 3		Fair Value at February 28, 2014
Financial Assets
Cash equivalents
Money market funds	$	445	$	—	$	—	$	445

Total	$	445	$	—	$	—	$	445

Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,807	$	1,807

Total		—		—		1,807		1,807

Total Financial Assets	$	445	$	—	$	1,807	$	2,252


Financial Liabilities
Interest rate swap agreements	$	—	$	594	$	—	$	594
Contingent liability for acquisition earn out		—		—		67,987		67,987

Total Financial Liabilities	$	—	$	594	$	67,987	$	68,581


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2013
	Level 1		Level 2		Level 3		Fair Value at May 31, 2013
Financial Assets
Cash equivalents
Money market funds	$	114	$	—	$	—	$	114

Total	$	114	$	—	$	—	$	114

Marketable securities
Corporate bond securities	$	—	$	303	$	—	$	303
U.S. government agency obligations		—		—		1,850		1,850

Total		—		303		1,850		2,153

Total Financial Assets	$	114	$	303	$	1,850	$	2,267


Financial Liabilities
Interest rate swap agreements	$	—	$	523	$	—	$	523
Contingent liability for acquisition earn out						75,049		75,049

Total Financial Liabilities	$	—	$	523	$	75,049	$	75,572

There were no significant transfers in and out of Level 1, 2 and 3 measurements for the nine months ended February 28, 2014.

The table below presents the components of Level 3 fair value instruments as of February 28, 2014 (in thousands of dollars):


	Financial Assets			Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs			Fair Value Measurements Using Significant Unobservable Inputs
	(Level 3)			(Level 3)
Balance, May 31, 2013	$	1,850		$	75,049
Total gains or losses (realized/unrealized):		—			—
Earnings revaluation gain - included in earnings		—			(4,994	)
Earnings revaluation expense - included in earnings		—			2,513
Included in other comprehensive income		(18	)		—
Purchases, issuances and settlements		(25	)		(9,551	)
Transfers in and/or (out) of Level 3		—			—
Contingent consideration - Clinical Devices		—			4,970

Balance, February 28, 2014	$	1,807		$	67,987

Contingent Liability for Acquisition Earn Outs

Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. Contingent consideration is recorded at the estimated fair value of the contingent milestone payments on the acquisition date. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements.

Contingent consideration liabilities will be remeasured to fair value each reporting period using projected net sales, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases in projected net sales and probabilities of payment may result in higher fair value measurements in the future. Increases in discount rates and the projected time to payment may result in lower fair value measurements in the future. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.

The recurring Level 3 fair value measurements of the contingent consideration liability related to the Vortex, Microsulis and Clinical Devices acquisitions include the following significant unobservable inputs as of February 28, 2014 (in thousands of dollars):


	Fair value at Feb 28, 2014		Valuation Technique	Unobservable Input	Range
Revenue based payments	$	63,487	Discounted cash flow	Discount rate	4%-10%
				Probability of payment	75-100%
				Projected fiscal year of payment	2014 - 2022

Milestone based payments	$	4,500	Discounted cash flow	Discount rate	16%-20%
			Discounted cash flow	Probability of payment	75-100%
				Projected fiscal year of payment	2014 - 2015

Total	$	67,987

At February 28, 2014, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $80.1 million. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2014 to 2022 in order for the consideration to be paid.

The fair value of contingent milestone payments associated with the acquisitions was remeasured as of February 28, 2014 and $55.8 million was reflected in “Contingent consideration, net of current portion” and $12.2 million was reflected in “Current portion of contingent consideration” on the consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments associated with the Vortex, Microsulis and Clinical Devices acquisitions measured at fair value that used significant unobservable inputs (Level 3) (in thousands of dollars):


Beginning balance - May 31, 2013	$	75,049
Purchase price contingent consideration for Clinical Devices		4,970
Contingent payments		(9,551	)
Earnings revaluation gain		(4,994	)
Earnings revaluation expense		2,513

Ending balance - February 28, 2014	$	67,987

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Marketable Securities

9 Months Ended

Feb. 28, 2014

Investments Debt And Equity Securities [Abstract]

Marketable Securities

NOTE K – MARKETABLE SECURITIES

Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” in accordance with authoritative guidance issued by FASB and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of February 28, 2014 and May 31, 2013, we had $1.80 million and $1.85 million, respectively, in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities.

As of February 28, 2014 and May 31, 2013, marketable securities consisted of the following (in thousands of dollars):


As of February 28, 2014	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sales securities
U.S. government agency obligations	$	1,825	$	—	$	(18	)	$	1,807

	$	1,825	$	—	$	(18	)	$	1,807


As of May 31, 2013	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sales securities
U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
Corporate bond securities		303		—		—		303

	$	2,153	$	—	$	—	$	2,153

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

Litigation	9 Months Ended
Litigation	Feb. 28, 2014
Commitments And Contingencies Disclosure [Abstract]
Litigation	NOTE L – LITIGATION *AngioDynamics v. biolitec* On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal. In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortiously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. On January 14, 2014, the District Court entered judgment in our favor as to liability. On March 18, 2014, the District Court entered judgment in our favor against Biolitec AG, Biomed Technology Holdings, Ltd., and Wolfgang Neuberger, jointly and severally, in the amount of $74.9 million. August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. The restraining order is still in place. Trial in the Bankruptcy Court is scheduled for June 12, 2014. *C.R. Bard, Inc. v. AngioDynamics, Inc.* On January 11, 2012, C.R. Bard, Inc. filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on patents held by Bard. Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office which seek to invalidate all three patents asserted in the litigation. Our petitions have been granted and 40 of 41 patent claims have been and remain rejected. The Patent Office has issued a Final Rejection of all the claims subject to reexamination and Bard has filed appeals. The parties are currently in the midst of the briefing process for these appeals. The case has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

Recently Issued Accounting Pronouncements	9 Months Ended
Recently Issued Accounting Pronouncements	Feb. 28, 2014
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	NOTE M – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In July 2013, the FASB issued guidance related to the presentation of certain tax information. This new pronouncement provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, or similar tax loss, or a tax credit carryforward exists. This pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2013 (our fiscal year 2015). Since the guidance only impacts presentation requirements, its adoption will not have a material impact on our consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 01

-Paragraph b

-Subparagraph 6

-Article 10

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

+ Details

Restructuring	9 Months Ended
Restructuring	Feb. 28, 2014
Restructuring And Related Activities [Abstract]
Restructuring	NOTE N – RESTRUCTURING On December 5, 2013, we announced a company-wide operational excellence program designed to save between $15 and $18 million during the course of the next three years. The initiative is expected to create greater efficiencies and drive business performance improvements by focusing on several key elements, including product rationalization, lean manufacturing initiatives, supply chain optimization and enterprise resource planning (ERP) implementation. The plan also incorporates the consolidation of our New York plants to establish a single manufacturing center in Glens Falls and a distribution center in Queensbury. During the course of the three-year program, it is expected that we will reduce our New York employee base by approximately 80-100 positions as a result of this plant consolidation and reorganization. Over the three year period, we expect to invest $5.4 million in facility improvements. In addition, total restructuring charges are estimated to be $4.7 million. The program was launched in the current fiscal quarter and the cost incurred was $1.0 million, consisting of $0.6 million of severance and related costs, $0.3 million of accelerated depreciation and $0.1 million in other costs. These costs are included in “Acquisition, restructuring and other items, net” in the statements of income.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details

Recently Issued Accounting Pronouncements (Policies)	9 Months Ended
Recently Issued Accounting Pronouncements (Policies)	Feb. 28, 2014
Accounting Changes And Error Corrections [Abstract]
Income Taxes	In July 2013, the FASB issued guidance related to the presentation of certain tax information. This new pronouncement provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, or similar tax loss, or a tax credit carryforward exists. This pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2013 (our fiscal year 2015). Since the guidance only impacts presentation requirements, its adoption will not have a material impact on our consolidated financial statements.

Inventories (Tables)

9 Months Ended

Feb. 28, 2014

Inventory Disclosure [Abstract]

Schedule of Inventories


	Feb 28, 2014		May 31, 2013
	(in thousands)
Raw materials	$	23,319	$	18,362
Work in process		13,353		11,006
Finished goods		23,162		25,694

Inventories	$	59,834	$	55,062

Goodwill and Intangible Assets (Tables)

9 Months Ended

Feb. 28, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill by Segment

Adjustments to goodwill for the nine months ended February 28, 2014 are as follows (in thousands of dollars):


Balance, May 31, 2013	$	355,458
Acquisition of Clinical Devices B.V.		4,278

Balance, February 28, 2014	$	359,736

Intangible Assets

As of February 28, 2014 and May 31, 2013, intangible assets consisted of the following (in thousands of dollars, except weighted average useful life):


	February 28, 2014
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	150,363	$	(31,060	)	$	119,303		10.2
Customer relationships		86,688		(36,412	)		50,276		11.9
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		6,290		(4,762	)		1,528		9.0
Trademarks		6,345		(1,682	)		4,663		8.0
In-process R&D acquired		3,600		—			3,600		Indefinite
Distributor relationships		900		(900	)		—		3.0

	$	282,786	$	(74,816	)	$	207,970


	May 31, 2013
	Gross carrying value		Accumulated amortization			Net carrying value		Weighted avg useful life
	(in thousands)							(years)
Product technologies	$	150,181	$	(24,835	)	$	125,346		10.6
Customer relationships		84,479		(30,595	)		53,884		14.8
Trademark-NAMIC		28,600		—			28,600		Indefinite
Licenses		6,302		(4,501	)		1,801		9.0
Trademarks		6,275		(1,058	)		5,217		9.9
Distributor relationships		900		(900	)		—		3.0

	$	276,737	$	(61,889	)	$	214,848

Accrued Liabilities (Tables)

9 Months Ended

Feb. 28, 2014

Payables And Accruals [Abstract]

Accrued Liabilities

As of February 28, 2014 and May 31, 2013, accrued liabilities consisted of the following (in thousands of dollars):


	Feb 28, 2014		May 31, 2013
	(in thousands)
Payroll and related expenses	$	7,529	$	6,491
Royalties		2,279		2,034
Accrued severance		1,491		1,602
Deferred revenue		1,471		1,573
Sales and franchise taxes		1,091		1,047
Interest rate swap liability		594		523
Other		4,511		3,156

Total	$	18,966	$	16,426

Income Taxes (Tables)

9 Months Ended

Feb. 28, 2014

Income Tax Disclosure [Abstract]

Components of Income Tax Expense/(Benefit)

The following table presents the components of income tax expense/(benefit) for the three and nine month periods ended February 28, 2014 and 2013 (in thousands of dollars):


	Three Months Ended						Nine Months Ended
	Feb 28, 2014			Feb 28, 2013			Feb 28, 2014			Feb 28, 2013

Income tax expense/(benefit) based on income/(loss) from continuing operations at estimated tax rates of 45.7% in 2014 and 70.3% in 2013	$	2,555		$	(1,280	)	$	2,217		$	110

Discrete tax expense/(benefit):

Non taxable gain on revaluation of contingent consideration liability at estimated tax rate of 45.7% in 2014		(2,285	)		—			(2,285	)		—

Adjustment for elimination of the ASC 718 APIC pool		57						123

Provision for change in projected tax rates		(50	)		601						—

Retroactive renewal of research and experimentation credit					(129	)					(129	)

Adjustments to prior period tax liabilities		156			(30	)		170			(3	)

Non deductible acquisition costs		—			9			—			102

Adjustment to fully reserved capital losses		43			—			43			(179	)


Total income tax expense/(benefit)	$	476		$	(829	)	$	268		$	(99	)

Earnings Per Share (Tables)

9 Months Ended

Feb. 28, 2014

Earnings Per Share [Abstract]

Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 28, 2014 and 2013 (in thousands):


	Three Months Ended				Nine Months Ended
	Feb 28, 2014		Feb 28, 2013		Feb 28, 2014		Feb 28, 2013
Basic		35,184		34,834		35,088		34,787
Effect of dilutive securities		520		—		284		528

Diluted		35,704		34,834		35,372		35,315

Segment and Geographic Information (Tables)

9 Months Ended

Feb. 28, 2014

Segment Reporting [Abstract]

Summary of Net Sales by Product Category

The table below summarizes net sales by product category (in thousands of dollars):


	Three Months Ended				Nine Months Ended
	Feb 28, 2014		Feb 28, 2013		Feb 28, 2014		Feb 28, 2013
Net sales
Peripheral Vascular	$	47,403	$	42,616	$	141,743	$	131,676
Vascular Access		27,259		26,391		78,113		79,733
Oncology/Surgery		11,968		10,449		35,692		33,688
Supply Agreement		1,565		2,115		4,842		6,897

Total	$	88,195	$	81,571	$	260,390	$	251,994

Summary of Net Sales by Geographic Area

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):


	Three Months Ended				Nine Months Ended
	Feb 28, 2014		Feb 28, 2013		Feb 28, 2014		Feb 28, 2013
Net Sales
United States	$	69,859	$	63,784	$	206,491	$	196,682
International		16,771		15,672		49,057		48,415
Supply Agreement		1,565		2,115		4,842		6,897

Total	$	88,195	$	81,571	$	260,390	$	251,994

Fair Value (Tables)

9 Months Ended

Feb. 28, 2014

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2014 and May 31, 2013 (in thousands of dollars):


	Fair Value Measurements using inputs considered as:						Fair Value at February 28, 2014
	Level 1		Level 2		Level 3		Fair Value at February 28, 2014
Financial Assets
Cash equivalents
Money market funds	$	445	$	—	$	—	$	445

Total	$	445	$	—	$	—	$	445

Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,807	$	1,807

Total		—		—		1,807		1,807

Total Financial Assets	$	445	$	—	$	1,807	$	2,252


Financial Liabilities
Interest rate swap agreements	$	—	$	594	$	—	$	594
Contingent liability for acquisition earn out		—		—		67,987		67,987

Total Financial Liabilities	$	—	$	594	$	67,987	$	68,581


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2013
	Level 1		Level 2		Level 3		Fair Value at May 31, 2013
Financial Assets
Cash equivalents
Money market funds	$	114	$	—	$	—	$	114

Total	$	114	$	—	$	—	$	114

Marketable securities
Corporate bond securities	$	—	$	303	$	—	$	303
U.S. government agency obligations		—		—		1,850		1,850

Total		—		303		1,850		2,153

Total Financial Assets	$	114	$	303	$	1,850	$	2,267


Financial Liabilities
Interest rate swap agreements	$	—	$	523	$	—	$	523
Contingent liability for acquisition earn out						75,049		75,049

Total Financial Liabilities	$	—	$	523	$	75,049	$	75,572

Fair Value Measurements Using Significant Unobservable Inputs

The table below presents the components of Level 3 fair value instruments as of February 28, 2014 (in thousands of dollars):


	Financial Assets			Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs			Fair Value Measurements Using Significant Unobservable Inputs
	(Level 3)			(Level 3)
Balance, May 31, 2013	$	1,850		$	75,049
Total gains or losses (realized/unrealized):		—			—
Earnings revaluation gain - included in earnings		—			(4,994	)
Earnings revaluation expense - included in earnings		—			2,513
Included in other comprehensive income		(18	)		—
Purchases, issuances and settlements		(25	)		(9,551	)
Transfers in and/or (out) of Level 3		—			—
Contingent consideration - Clinical Devices		—			4,970

Balance, February 28, 2014	$	1,807		$	67,987

Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability


	Fair value at Feb 28, 2014		Valuation Technique	Unobservable Input	Range
Revenue based payments	$	63,487	Discounted cash flow	Discount rate	4%-10%
				Probability of payment	75-100%
				Projected fiscal year of payment	2014 - 2022

Milestone based payments	$	4,500	Discounted cash flow	Discount rate	16%-20%
			Discounted cash flow	Probability of payment	75-100%
				Projected fiscal year of payment	2014 - 2015

Total	$	67,987

Summary Showing Reconciliation of the Contingent Payments


Beginning balance - May 31, 2013	$	75,049
Purchase price contingent consideration for Clinical Devices		4,970
Contingent payments		(9,551	)
Earnings revaluation gain		(4,994	)
Earnings revaluation expense		2,513

Ending balance - February 28, 2014	$	67,987

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References+ Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Marketable Securities (Tables)

9 Months Ended

Feb. 28, 2014

Investments Debt And Equity Securities [Abstract]

Marketable Securities

As of February 28, 2014 and May 31, 2013, marketable securities consisted of the following (in thousands of dollars):


As of February 28, 2014	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sales securities
U.S. government agency obligations	$	1,825	$	—	$	(18	)	$	1,807

	$	1,825	$	—	$	(18	)	$	1,807


As of May 31, 2013	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sales securities
U.S. government agency obligations	$	1,850	$	—	$	—	$	1,850
Corporate bond securities		303		—		—		303

	$	2,153	$	—	$	—	$	2,153

Consolidated Financial Statements - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	0 Months Ended	1 Months Ended				9 Months Ended		0 Months Ended			1 Months Ended				9 Months Ended		1 Months Ended				9 Months Ended		1 Months Ended
	Dec. 05, 2013	Nov. 28, 2012 Observations	Sep. 24, 2012 Observations	Feb. 13, 2012 Observations	Feb. 10, 2012 Observations	Feb. 28, 2014	Feb. 28, 2014 Clinical Devices B.V [Member]	Dec. 05, 2013 Minimum [Member]	Dec. 05, 2013 Maximum [Member]	Mar. 31, 2014 Subsequent Event [Member] Observations	Sep. 19, 2013 New Credit Agreement [Member] Agreement	Sep. 19, 2013 New Credit Agreement [Member] Minimum [Member]	Sep. 19, 2013 New Credit Agreement [Member] Maximum [Member]	Sep. 19, 2013 New Credit Agreement [Member] Term Loan Facility [Member]	Feb. 28, 2014 New Credit Agreement [Member] Term Loan Facility [Member]	Sep. 19, 2013 New Credit Agreement [Member] Senior Secured Revolving Credit Facility [Member]	Sep. 19, 2013 New Credit Agreement [Member] Senior Secured Revolving Credit Facility [Member] Minimum [Member]	Sep. 19, 2013 New Credit Agreement [Member] Senior Secured Revolving Credit Facility [Member] Maximum [Member]	Sep. 19, 2013 New Credit Agreement [Member] Letters of Credit [Member]	Sep. 19, 2013 New Credit Agreement [Member] Swingline Loans [Member]	Feb. 28, 2014 New Credit Agreement [Member] Revolving Credit Facility [Member]	Sep. 19, 2013 New Credit Agreement [Member] Revolving Credit Facility [Member]	Sep. 19, 2013 New Credit Agreement [Member] Base Rate [Member] JP Morgan Chase [Member]	Sep. 19, 2013 New Credit Agreement [Member] Eurodollar [Member] JP Morgan Chase [Member]
Recent Developments [Line Items]
Expected savings due to operational excellence program over three years								$ 15	$ 18
Operational excellence program period	3 years
Senior secured term loan facility														100		100			20	5
Percentage of quarterly repayment of term facility, year one														5.00%
Percentage of quarterly repayment of term facility, year two														5.00%
Percentage of quarterly repayment of term facility, year three														10.00%
Percentage of quarterly repayment of term facility, year four														15.00%
Percentage of quarterly repayment of term facility, year five														65.00%
Bank credit agreement maturity period														In years one through five
Maturity period of Revolving Facility															5 years						5 years
Percentage of increases leverage ratio base rate, minimum																							0.50%	1.50%
Percentage of increases leverage ratio base rate, maximum																							1.25%	2.25%
Percentage of increase in interest											2.00%
Commitment fee, percentage																	0.20%	0.35%
Initial amount borrowed under revolving facility																						41.4
Number of financial covenants											2
Credit facility, amount outstanding															92.5						41.4
Covenant ratio range												Not less than 1.35 to 1.00	Not greater than 3.75 to 1.00
Date of business acquisition							Aug. 15, 2013
Costs for Quality Call to Action Program						$ 3.2
Number of observations		0	5	6	12					3
Number of business days to provide responses to FDA						15 days

Acquisitions - Additional Information (Detail) (USD $)			9 Months Ended			9 Months Ended			9 Months Ended			1 Months Ended	9 Months Ended	12 Months Ended	1 Months Ended	9 Months Ended	12 Months Ended	1 Months Ended
Acquisitions - Additional Information (Detail) (USD $)	Feb. 28, 2014	May 31, 2013	Feb. 28, 2014 Minimum [Member]	Feb. 28, 2014 Maximum [Member]	Aug. 15, 2013 Clinical Devices B.V [Member]	Feb. 28, 2014 Microsulis Medical Ltd. [Member]	Dec. 31, 2013 Microsulis Medical Ltd. [Member]	Feb. 01, 2013 Microsulis Medical Ltd. [Member]	Feb. 28, 2014 Microsulis Medical Ltd. [Member] Minimum [Member]	Feb. 28, 2014 Microsulis Medical Ltd. [Member] Maximum [Member]	Feb. 28, 2014 Vortex Medical, Inc. [Member]	Aug. 15, 2013 In-process Research and Development [Member] Clinical Devices B.V [Member]	Feb. 28, 2014 Customer Relationships [Member]	May 31, 2013 Customer Relationships [Member]	Aug. 15, 2013 Customer Relationships [Member] Clinical Devices B.V [Member]	Feb. 28, 2014 Trademarks [Member]	May 31, 2013 Trademarks [Member]	Aug. 15, 2013 Trademarks [Member] Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Cash payments at closing total					$ 3,700,000	$ 10,500,000		$ 10,000,000			$ 15,100,000
Business acquisition purchase price holdback amount					400,000
Total purchase					8,700,000	33,600,000	5,000,000				75,300,000
Present value of contingent consideration liability					5,000,000	13,200,000					60,300,000
Goodwill acquired	359,736,000	355,458,000			4,300,000	19,300,000					29,500,000
Intangible assets other than goodwill					5,100,000
Acquired finite lived intangible assets												3,600,000			1,400,000			100,000
Estimated useful life			3 years	15 years					10 years	15 years	15 years	10 years	11 years 10 months 24 days	14 years 9 months 18 days	15 years	8 years	9 years 10 months 24 days	5 years
Deferred tax liability					1,200,000
Business acquisition cost of acquired entity purchase price payable						5,000,000		5,000,000
Liabilities assumed								1,600,000
Additional cash consideration payable period						9 years
Investment in company						5,000,000
Acquisition related costs						100,000
Fair value of guaranteed contingent consideration											$ 40,000,000

Inventories - Schedule of Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Feb. 28, 2014	May 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$ 23,319	$ 18,362
Work in process	13,353	11,006
Finished goods	23,162	25,694
Inventories	$ 59,834	$ 55,062

Goodwill and Intangible Assets - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended	9 Months Ended
	Dec. 31, 2013 Reporting_Unit Segment	Feb. 28, 2014 Segment
Finite-Lived Intangible Assets [Line Items]
Number of reportable unit	1
Number of operating segment	1	1
Terminal value of the reporting unit	7.0
Discount rate used in fair value calculation	12.00%
Percentage of fair value, carrying value	6.00%
Goodwill impairment	$ 0
Income Approach [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of weightage to determine fair value		75.00%
Discount rate used in fair value calculation	12.50%
Percentage of fair value, carrying value	6.00%
Long-term growth rate used in fair value calculation	5.00%
Royalty rate used in fair value calculation	3.00%
Market Approach [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of weightage to determine fair value		25.00%
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		15 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		3 years

Goodwill and Intangible Assets - Goodwill by Segment (Detail) (USD $) In Thousands, unless otherwise specified			9 Months Ended
	Feb. 28, 2014	May 31, 2013	Feb. 28, 2014 Clinical Devices B.V [Member]	Aug. 15, 2013 Clinical Devices B.V [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance	$ 359,736	$ 355,458		$ 4,300
Acquisition			4,278
Goodwill, Ending Balance	$ 359,736	$ 355,458		$ 4,300

Goodwill and Intangible Assets - Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Feb. 28, 2014	May 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 282,786	$ 276,737
Accumulated amortization	(74,816)	(61,889)
Net carrying value	207,970	214,848
Product Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	150,363	150,181
Accumulated amortization	(31,060)	(24,835)
Net carrying value	119,303	125,346
Weighted avg useful life	10 years 2 months 12 days	10 years 7 months 6 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	86,688	84,479
Accumulated amortization	(36,412)	(30,595)
Net carrying value	50,276	53,884
Weighted avg useful life	11 years 10 months 24 days	14 years 9 months 18 days
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	6,290	6,302
Accumulated amortization	(4,762)	(4,501)
Net carrying value	1,528	1,801
Weighted avg useful life	9 years	9 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	6,345	6,275
Accumulated amortization	(1,682)	(1,058)
Net carrying value	4,663	5,217
Weighted avg useful life	8 years	9 years 10 months 24 days
Distributor Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	900	900
Accumulated amortization	(900)	(900)
Net carrying value
Weighted avg useful life	3 years	3 years
Trademark-NAMIC [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	28,600	28,600
Accumulated amortization
Net carrying value	28,600	28,600
In-process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	3,600
Accumulated amortization
Net carrying value	$ 3,600

Accrued Liabilities - Summary of Accrued Liabilities (Detail) (USD $) In Thousands, unless otherwise specified	Feb. 28, 2014	May 31, 2013
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$ 7,529	$ 6,491
Royalties	2,279	2,034
Accrued severance	1,491	1,602
Deferred revenue	1,471	1,573
Sales and franchise taxes	1,091	1,047
Interest rate swap liability	594	523
Other	4,511	3,156
Total	$ 18,966	$ 16,426

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Long Term Debt - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended	9 Months Ended
	Sep. 19, 2013	Feb. 28, 2014
Debt Instrument [Line Items]
Notional amount of interest rate swap agreement		$ 100
Fixed interest rate payments		0.74%
New Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of increase in interest	2.00%
Number of financial covenants	2
New Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Covenant ratio range	Not less than 1.35 to 1.00
New Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Covenant ratio range	Not greater than 3.75 to 1.00
New Credit Agreement [Member] \| Base Rate [Member] \| JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] \| Eurodollar [Member] \| JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%
New Credit Agreement [Member] \| Term Loan Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	100
Percentage of quarterly repayment of term facility year one	5.00%
Percentage of quarterly repayment of term facility year two	5.00%
Percentage of quarterly repayment of term facility year three	10.00%
Percentage of quarterly repayment of term facility year four	15.00%
Percentage of quarterly repayment of term facility year five	65.00%
Bank credit agreement maturity period	In years one through five
Maturity period of Revolving Facility		5 years
Credit facility, amount outstanding		92.5
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	100
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
New Credit Agreement [Member] \| Senior Secured Revolving Credit Facility [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
New Credit Agreement [Member] \| Letters of Credit [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	20
New Credit Agreement [Member] \| Swingline Loans [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	5
New Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maturity period of Revolving Facility		5 years
Initial amount borrowed under revolving facility	41.4
Credit facility, amount outstanding		$ 41.4

Income Taxes - Components of Income Tax Expense/(Benefit) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Income Tax Disclosure [Abstract]
Income tax expense/(benefit) based on income/(loss) from continuing operations at estimated tax rates of 45.7% in 2014 and 70.3% in 2013	$ 2,555	$ (1,280)	$ 2,217	$ 110
Discrete tax expense/(benefit):
Non taxable gain on revaluation of contingent consideration liability at estimated tax rate of 45.7% in 2014	(2,285)		(2,285)
Adjustment for elimination of the ASC 718 APIC pool	57		123
Provision for change in projected tax rates	(50)	601
Retroactive renewal of research and experimentation credit		(129)		(129)
Adjustments to prior period tax liabilities	156	(30)	170	(3)
Non deductible acquisition costs		9		102
Adjustment to fully reserved capital losses	43		43	(179)
Total income tax expense/(benefit)	$ 476	$ (829)	$ 268	$ (99)

Income Taxes - Components of Income Tax Expense/(Benefit) (Parenthetical) (Detail)	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Income Tax Disclosure [Abstract]
Estimated tax rate	45.70%	70.30%	45.70%	70.30%

Income Taxes - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Income Tax Contingency [Line Items]
Effective income tax rate	45.70%	70.30%	45.70%	70.30%
2015 to 2023 [Member]
Income Tax Contingency [Line Items]
Expected taxable income every year to utilize operating loss carryforwards			$ 9.3
Until 2031 [Member]
Income Tax Contingency [Line Items]
Expected taxable income every year to utilize operating loss carryforwards			$ 6.5

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Earnings Per Share [Abstract]
Basic	35,184	34,834	35,088	34,787
Effect of dilutive securities	520		284	528
Diluted	35,704	34,834	35,372	35,315

Earnings Per Share - Additional Information (Detail) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of diluted earnings per share	0.7	2.9	2.3	2.9

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Segment and Geographic Information - Additional Information (Detail)	1 Months Ended	9 Months Ended
	Dec. 31, 2013 Segment	Feb. 28, 2014 Segment
Segment Reporting [Abstract]
Number of segment	1	1

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Segment Reporting Information [Line Items]
Net sales	$ 88,195	$ 81,571	$ 260,390	$ 251,994
Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	47,403	42,616	141,743	131,676
Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	27,259	26,391	78,113	79,733
Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	11,968	10,449	35,692	33,688
Supply Agreement [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,565	$ 2,115	$ 4,842	$ 6,897

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013
Net Sales
Net sales	$ 88,195	$ 81,571	$ 260,390	$ 251,994
Supply Agreement [Member]
Net Sales
Net sales	1,565	2,115	4,842	6,897
Reportable Geographical Components [Member] \| United States [Member]
Net Sales
Net sales	69,859	63,784	206,491	196,682
Reportable Geographical Components [Member] \| International [Member]
Net Sales
Net sales	16,771	15,672	49,057	48,415
Reportable Geographical Components [Member] \| Supply Agreement [Member]
Net Sales
Net sales	$ 1,565	$ 2,115	$ 4,842	$ 6,897

Fair Value - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Feb. 28, 2014 Securities
Fair Value Disclosures [Abstract]
Number of auction rate securities	1
Potential amount of undiscounted future contingent consideration	$ 80.1
Fair value of contingent milestone payments, long term portion	12.2
Fair value of contingent milestone payments, current portion	$ 55.8

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) (Recurring [Member], USD $) In Thousands, unless otherwise specified	Feb. 28, 2014	May 31, 2013
Financial Assets
Cash equivalents	$ 445	$ 114
Marketable securities	1,807	2,153
Total Financial Assets	2,252	2,267
Financial Liabilities
Total Financial Liabilities	68,581	75,572
Money Market Funds [Member]
Financial Assets
Cash equivalents	445	114
Corporate Bond Securities [Member]
Financial Assets
Marketable securities		303
U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,807	1,850
Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities	594	523
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	67,987	75,049
Level 1 [Member]
Financial Assets
Cash equivalents	445	114
Marketable securities
Total Financial Assets	445	114
Financial Liabilities
Total Financial Liabilities
Level 1 [Member] \| Money Market Funds [Member]
Financial Assets
Cash equivalents	445	114
Level 1 [Member] \| Corporate Bond Securities [Member]
Financial Assets
Marketable securities
Level 1 [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities
Level 1 [Member] \| Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities
Level 1 [Member] \| Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities
Level 2 [Member]
Financial Assets
Cash equivalents
Marketable securities		303
Total Financial Assets		303
Financial Liabilities
Total Financial Liabilities	594	523
Level 2 [Member] \| Money Market Funds [Member]
Financial Assets
Cash equivalents
Level 2 [Member] \| Corporate Bond Securities [Member]
Financial Assets
Marketable securities		303
Level 2 [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities
Level 2 [Member] \| Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities	594	523
Level 2 [Member] \| Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities
Level 3 [Member]
Financial Assets
Cash equivalents
Marketable securities	1,807	1,850
Total Financial Assets	1,807	1,850
Financial Liabilities
Total Financial Liabilities	67,987	75,049
Level 3 [Member] \| Money Market Funds [Member]
Financial Assets
Cash equivalents
Level 3 [Member] \| Corporate Bond Securities [Member]
Financial Assets
Marketable securities
Level 3 [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,807	1,850
Level 3 [Member] \| Interest Rate Swap Agreements [Member]
Financial Liabilities
Total Financial Liabilities
Level 3 [Member] \| Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	$ 67,987	$ 75,049

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Feb. 28, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance, May 31, 2013, Financial Assets	$ 1,850
Total gains or losses (realized/unrealized):
Earnings revaluation gain - included in earnings, Financial Assets
Earnings revaluation expense - included in earnings, Financial Assets
Included in other comprehensive income, Financial Assets	(18)
Purchases, issuances and settlements, Financial Assets	(25)
Transfers in and/or (out) of Level 3, Financial Assets
Balance, February 28, 2014, Financial Assets	1,807
Balance, May 31, 2013, Financial Liabilities	75,049
Earnings revaluation gain - included in earnings, Financial Liabilities	(4,994)
Earnings revaluation expense - included in earnings, Financial Liabilities	2,513
Included in other comprehensive income, Financial Liabilities
Purchases, issuances and settlements, Financial Liabilities	(9,551)
Transfers in and/or (out) of Level 3, Financial Liabilities
Balance, February 28, 2014, Financial Liabilities	67,987
Clinical Devices B.V [Member]
Total gains or losses (realized/unrealized):
Contingent consideration - Clinical Devices, Financial Assets
Contingent consideration - Clinical Devices, Financial Liabilities	$ 4,970

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) (USD $) In Thousands, unless otherwise specified					9 Months Ended			9 Months Ended
	Feb. 28, 2014	May 31, 2013	Feb. 28, 2014 Level 3 [Member] Contingent Consideration Earn Out Liability [Member]	Feb. 28, 2014 Level 3 [Member] Revenue Based Payments [Member] Recurring [Member] Contingent Consideration Earn Out Liability [Member]	Feb. 28, 2014 Level 3 [Member] Revenue Based Payments [Member] Minimum [Member] Recurring [Member] Contingent Consideration Earn Out Liability [Member]	Feb. 28, 2014 Level 3 [Member] Revenue Based Payments [Member] Maximum [Member] Recurring [Member] Contingent Consideration Earn Out Liability [Member]	Feb. 28, 2014 Level 3 [Member] Milestone Based Payments [Member] Recurring [Member] Contingent Consideration Earn Out Liability [Member]	Feb. 28, 2014 Level 3 [Member] Milestone Based Payments [Member] Minimum [Member] Recurring [Member] Contingent Consideration Earn Out Liability [Member]	Feb. 28, 2014 Level 3 [Member] Milestone Based Payments [Member] Maximum [Member] Recurring [Member] Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Revenue based payments	$ 67,987	$ 75,049	$ 67,987	$ 63,487			$ 4,500
Discount rate					4.00%	10.00%		16.00%	20.00%
Probability of payment					75.00%	100.00%		75.00%	100.00%
Projected fiscal year of payment					2014	2022		2014	2015

Fair Value - Summary Showing Reconciliation of the Contingent Payments (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Feb. 28, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Earnings revaluation gain	$ (4,994)
Earnings revaluation expense	2,513
Contingent Consideration Earn Out Liability [Member] \| Vortex, Microsulis and Clinical Devices [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - May 31, 2013	75,049
Purchase price contingent consideration for Clinical Devices	4,970
Contingent payments	(9,551)
Earnings revaluation gain	(4,994)
Earnings revaluation expense	2,513
Ending balance - February 28, 2014	$ 67,987

Marketable Securities - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	Feb. 28, 2014 Investment	May 31, 2013 Investment
Marketable Securities [Abstract]
Investments in auction rate securities that failed auctions	$ 1.80	$ 1.85
Number of investments	2	2

Marketable Securities - Marketable Securities (Detail) (USD $) In Thousands, unless otherwise specified	Feb. 28, 2014	May 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,825	$ 2,153
Gross Unrealized Gains
Gross Unrealized Losses	(18)
Fair Value	1,807	2,153
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,825	1,850
Gross Unrealized Gains
Gross Unrealized Losses	(18)
Fair Value	1,807	1,850
Corporate Bond Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost		303
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value		$ 303

Litigation - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	0 Months Ended	1 Months Ended		9 Months Ended
	Mar. 18, 2014 Subsequent Event [Member]	Nov. 08, 2012 Biolitec [Member]	Feb. 28, 2014 Biolitec [Member] Lawsuits	Feb. 28, 2014 C.R. Bard, Inc. [Member] Petition
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification			2
Partial judgment granted		$ 23.2
Litigation settlement amount	$ 74.9
Number of petitions filed for reexamination of patents				3
Number of patent claims rejected				40 of 41 patent

Restructuring - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	0 Months Ended	3 Months Ended
	Dec. 05, 2013	Feb. 28, 2014
Restructuring Cost and Reserve [Line Items]
Operational excellence program period	3 years
Invest in facility improvements	$ 5.4
Estimated restructuring charges	4.7
Cost incurred to launch program		1.0
Severance and related costs		0.6
Accelerated depreciation		0.3
Other costs		0.1
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected savings due to operational excellence program over three years	15
Number of positions expected to be eliminated as a result of restructuring activities	80
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected savings due to operational excellence program over three years	$ 18
Number of positions expected to be eliminated as a result of restructuring activities	100